|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E alleles are important genetic markers for dyslipidemia and CHD.
|
7966894 |
1994 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins.
|
7706948 |
1995 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To determine whether the risk of obesity-associated dyslipidemia in children is influenced by apolipoprotein E (apoE) polymorphism, we studied 137 obese, nongenetically related children aged 2.2-14.4 y (mean age, 9.9 +/- 3.1 y) with a weight-for-height excess of 43.7 +/- 17.9%.
|
9128291 |
1997 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E polymorphism in indigenous Australians: allelic frequencies and relationship with dyslipidaemia.
|
10078180 |
1999 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Presence of APOE epsilon4/* seems to increase the risk for dementia and AD independently of its effect on dyslipidemia and atherogenesis.
|
10668701 |
2000 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ApoE4 allele is associated with obesity independent of dyslipidemia in women but not men with a family history of diabetes.
|
11553047 |
2001 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Apolipoprotein E (apo E) deficiency (or its abnormalities in humans) is associated with a series of pathological conditions including dyslipidemia, atherosclerosis, Alzheimer's disease, and shorter life span.
|
11726538 |
2001 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, apo E gene locus influences not only the levels of certain lipoprotein variables during young adulthood, but also modulates the association between obesity and dyslipidemias.
|
11398147 |
2001 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Apolipoprotein E (apo E), a genetic determinant of plasma lipid levels and coronary heart disease (CHD) needs to be investigated in Asian Indians since they have a propensity to develop dyslipidemia and accelerated atherosclerosis.
|
12030385 |
2002 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, Apo E4 has a larger impact than Apo E2 on fasting-lipid profile in PTX candidates, and Apo E gene polymorphism does not worsen lipid dyslipidemia after PTX, despite introduction of immunosuppressant medications known to cause dyslipidemia.
|
12394840 |
2002 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Such findings support the active role of placental LPL and APOE in the metabolism of maternal lipoproteins and suggest that fetal genes may modulate the risk for problems related to maternal dyslipidemia (preeclampsia, pancreatitis, and future cardiovascular disease).
|
16106048 |
2005 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Further screening for common apoE gene variants in individuals at risk for dyslipidemia may reveal abnormal heteroduplex patterns and uncover further mutations in this important lipid-regulating gene.
|
15514092 |
2005 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We evaluated the contribution of APOC3 -482C-->T, -455T-->C, and 3238C-->G; epsilon 2 and epsilon 4 alleles of APOE; and TNF -238G-->A to dyslipidemia and lipoatrophy by longitudinally modeling >2600 lipid determinations and 2328 lipoatrophy assessments in 329 ART-treated patients during a median follow-up period of 3.4 years.
|
15809899 |
2005 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
APOE genotypes and dyslipidemias in a sample of the Portuguese population.
|
16176168 |
2005 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this population, we analyzed the relationship between background risk factors [age, gender, the G1691A polymorphisms of factor V gene, the C677T polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene, the 844ins68bp polymorphisms of the cystathionine-beta-synthase (CBS) gene, and the apolipoprotein E (APOE) polymorphisms] and environmental risk factors, both atherogenic (smoke, hypertension, diabetes, dyslipidemia, obesity) and thrombogenic (smoke, homocysteine, fibrinogen) by a Markov block-recursive modeling approach.
|
16194201 |
2005 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E polymorphism is an important genetic marker for dyslipidemia.
|
16142566 |
2005 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A similar phenotype of combined dyslipidemia was induced in apoE(-/-) or apoE(-/-) x LDLr(-/-) mice after infection with a low dose (4 x 10(8) pfu) of an adenovirus expressing the apoE4[R142V/R145V] mutant previously shown to be defective in receptor binding.
|
16339113 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The objective of this study was to evaluate 1) whether non single nucleotide polymorphisms-coding (non-cSNP) in the apolipoprotein E gene (APOE) identified by resequencing studies contribute to statistically explaining dyslipidemia if variations in the two cSNPs in exon 4 that define the 2, 3, and 4 alleles are ignored, and 2) whether the contribution of these additional SNPs persists when variations in the cSNPs are considered.
|
16317171 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Polymorphism of the apolipoprotein E (APOE) gene has been associated with dyslipidemia and cardiovascular disease.
|
16815257 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The objective of this study was to evaluate 1) whether non single nucleotide polymorphisms-coding (non-cSNP) in the apolipoprotein E gene (APOE) identified by resequencing studies contribute to statistically explaining dyslipidemia if variations in the two cSNPs in exon 4 that define the 2, 3, and 4 alleles are ignored, and 2) whether the contribution of these additional SNPs persists when variations in the cSNPs are considered.
|
16317171 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The purpose of this study was to evaluate the effect of apolipoprotein E polymorphism on lipid-lowering response to treatment with atorvastatin and fenofibrate in patients with different types of dyslipidemia.
|
17056835 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The purpose of this study was to evaluate the effect of apolipoprotein E polymorphism on lipid-lowering response to treatment with atorvastatin and fenofibrate in patients with different types of dyslipidemia.
|
17056835 |
2006 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein.
|
17655277 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Compared with APOE*3/*3 homozygotes, patients with the APOE*4 allele had 1.3 times higher risk for CAD after ignoring dyslipidemia, but this risk was modified after adjusting for dyslipidemia.
|
17985658 |
2007 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The present study indicates that in the Ouro Preto admixed population the presence of APOE *2 can confer a protective effect, whereas the presence of APOE *4 implies an enhanced risk for dyslipidemia.
|
17224996 |
2007 |